Biologics

Pacira Biosciences completed its acquisition of Flexion Therapeutics, according to a Nov. 19 news release.

Orthobiologics company Bioventus has signed a lease agreement to double its current operations and manufacturing space in Cordova, Tenn.

A spine biologics company's $100 million investment deal and six more key updates in regenerative medicine in the last two months:

Houston-based FibroBiologics, a regenerative medicine company developing treatments for chronic disease using fibroblast cells, signed an agreement with a private investment group that will provide the company with up to $100 million over the next three years.

The number of businesses and medical clinics advertising stem cell-based therapies has skyrocketed in the U.S. over the past five years, according to a study published in Cell Stem Cell Nov. 4. 

Over the past few decades, rates of spinal fusions have steadily risen. However, pseudarthrosis rates— an indicator of unsuccessful spinal fusion — have not improved enough in the past 20 years to reduce the overall non-unions. With a growing number of…

Pacira Biosciences reported an uptick in total sales and its Exparel injectable analgesic during the third quarter.

Pacira Biosciences reached a milestone with its patent for the Exparel injectable analgesic, the company said Nov. 2.

Stockholders approved Bioventus' planned acquisition of Misonix.

Medtronic will no longer distribute Aziyo Biologics' cellular bone matrix products.